Apremilast as a potential treatment for moderate to severe dermatomyositis: A retrospective study of 3 patients

Carole Bitar; Jalal Maghfour; Hoang Ho-Pham; Brittany Stumpf; Erin Boh

doi:10.1016/j.jdcr.2018.11.019

Apremilast as a potential treatment for moderate to severe dermatomyositis: A retrospective study of 3 patients

JAAD Case Rep. 2019 Jan 30;5(2):191-194. doi: 10.1016/j.jdcr.2018.11.019. eCollection 2019 Feb.

Authors

Carole Bitar¹, Jalal Maghfour², Hoang Ho-Pham³, Brittany Stumpf¹, Erin Boh¹

Affiliations

¹ Department of Dermatology, Tulane University, New Orleans, Louisiana.
² Tulane Medical School, New Orleans, Louisiana.
³ Louisiana State University School of Medicine, New Orleans, Louisiana.

No abstract available

Keywords: CDASI, Cutaneous Dermatomyositis Activity And Severity Index; CK, creatine kinase; IL, interleukin (),; PDE-4, phosphodiesterase-4; Th1, T helper-1; Th2, T helper-2; apremilast; dermatomyositis.

Publication types

Case Reports